Genetic Inflammation Networks in Mouse Brain
2026-08-11
Xiong and colleagues developed a scalable bulk RNA-sequencing and analysis framework to resolve modular inflammatory states in genetically heterogeneous mouse brains. By comparing six ENU-associated disease-relevant mutations, the study distinguishes shared microglial disturbances from mutation-specific astrocyte and microglia activation, providing a practical strategy for interpreting complex CNS transcriptomes.
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody
2026-08-10
This Cy3-conjugated secondary antibody detects goat IgG in fluorescence-based ICC/IF, IHC, flow cytometry, and ELISA workflows. It should be used with goat-derived IgG primary antibodies and not treated as a universal reagent for non-goat immunoglobulins, non-IgG targets, or unvalidated live-cell applications.
Elobixibat Hydrate: IBAT Mechanism & Evidence
2026-08-09
Elobixibat hydrate is a selective ileal bile acid transporter inhibitor that increases distal intestinal bile acid signaling and supports bowel motility. A small 12-week pilot study in patients with type 2 diabetes mellitus and constipation reported improvements in HbA1c, LDL cholesterol, and constipation-related outcomes, but larger controlled studies are still needed.
AM 281 and the CB1–CREB–GLT-1 Axis
2026-08-08
A translational perspective on how AM 281 enables selective interrogation of CB1 signaling, astrocytic GLT-1 regulation, glutamate excitotoxicity, and cognitive dysfunction across neuropharmacology research models.
Trifluoperazine 2HCl: From Target to Assay
2026-08-07
Trifluoperazine 2HCl is a potent dopamine D2 receptor inhibitor for mechanistic neuropharmacology research. This guide connects receptor pharmacology, assay architecture, cross-domain applications, and lessons from PDK4 inhibitor discovery to improve experimental interpretation.
Trelagliptin Succinate: Pathways, Protocols, and Cognitive I
2026-08-07
Explore Trelagliptin succinate as more than a DPP-4 inhibitor—uncover its advanced mechanisms, unique neuroprotective effects in diabetes models, and protocol guidance for translational research. This article provides a new perspective on SYR-472 succinate, bridging metabolic and cognitive domains.
SmD2 Acetylation Regulates PARP Inhibitor Sensitivity in HCC
2026-08-06
This study identifies acetylation-dependent regulation of the spliceosome core protein SmD2 as a key determinant of DNA repair and PARP inhibitor sensitivity in hepatocellular carcinoma (HCC). The findings reveal a new mechanistic link between spliceosome function, alternative splicing, and therapeutic vulnerability in BRCA-proficient HCC, suggesting novel combinatorial strategies for cancer research.
Trelagliptin Succinate Improves Insulin Resistance via PI3K/
2026-08-06
This study elucidates how Trelagliptin succinate (SYR-472 succinate), a long-acting DPP-4 inhibitor, enhances insulin sensitivity in adipocytes by modulating the PI3K/Akt/GLUT4 signaling pathway. The findings reveal new mechanistic insights relevant for type 2 diabetes treatment research and offer protocol strategies for cellular models of insulin resistance.
N3-kethoxal: Precision RNA Structure Probing and DNA Mapping
2026-08-05
N3-kethoxal empowers researchers to map RNA secondary structures and accessible DNA regions with unparalleled selectivity for unpaired guanine bases. Its compatibility with bioorthogonal click chemistry unlocks streamlined workflows for nucleic acid structure-function studies and CRISPR specificity profiling.
Nav1.5 Ser571 Phosphorylation Drives Age-Related Cardiac Dys
2026-08-05
This study demonstrates that phosphorylation of the cardiac sodium channel Nav1.5 at Ser571 is a pivotal event increasing late sodium current in aging hearts. The findings clarify molecular links between altered sodium channel regulation, delayed myocardial repolarization, and diastolic dysfunction, guiding targeted research strategies for arrhythmia prevention in the elderly.
Angiotensin Peptides Potentiate SARS-CoV-2 Spike–Receptor Bi
2026-08-04
The referenced study demonstrates that naturally occurring angiotensin peptides, including Angiotensin III, significantly enhance the binding of the SARS-CoV-2 spike protein to its cellular receptors, especially AXL. This mechanistic insight reveals a novel interface between the renin–angiotensin–aldosterone system and viral pathogenesis, with implications for both cardiovascular and infectious disease research.
Triacetin (Glyceryl Triacetate): Epigenetic Modulation & Met
2026-08-04
Explore the multifaceted capabilities of Triacetin (glyceryl triacetate) as an epigenetic modulator and metabolic regulator in advanced biochemical assays. This article delivers unique, in-depth analysis not found in other resources, with protocol insights and translational guidance for innovative research.
FPH1 (BRD-6125): Driving Functional Hepatocyte Proliferation
2026-08-03
FPH1 (BRD-6125) enables robust, donor-independent expansion of primary human hepatocytes, setting a new benchmark for hepatic cell models in drug discovery and regenerative research. This article breaks down optimized protocols, applied workflows, and troubleshooting strategies to unlock the full potential of this small molecule enhancer.
SM-102: Ionizable Lipid for Efficient mRNA Vaccine Delivery
2026-08-03
SM-102, or heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate, is a synthetic lipid pivotal in mRNA delivery systems. As a component of lipid nanoparticles, it enhances cellular mRNA uptake and endosomal escape, significantly advancing mRNA vaccine technology.
Parthenolide Triggers ROS-Driven Apoptosis in Lymphoid Malig
2026-08-02
Jorge et al. (2023) demonstrate that parthenolide induces apoptosis in a spectrum of lymphoid malignancy cell lines via ROS generation and mitochondrial dysfunction. Their work highlights both the mechanistic diversity of parthenolide's action and the utility of sensitive cell viability assays in profiling therapeutic responses.
460 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page